title: Cardioprotective effect of dexrazoxane in a rat model of myocardial infarction: anti-apoptosis and promoting angiogenesis.
abstract: OBJECTIVE
  Dexrazoxane (DZR) is a clinically approved agent for preventive treatment of doxorubicin-induced cardiotoxicity. The objective of this study was to investigate the cardioprotective effects of DZR in a rat model of myocardial infarction (MI).
  
  
  METHODS
  Sprague-Dawley rats were randomly divided into four groups: MI (n = 16), MI + DZR (n = 16), SHAM-operated (n = 14) and DZR-only (n = 9). MI animals were subjected to left anterior descending coronary artery ligation. DZR was administered as a single dose at 125 mg/kg intraperitoneally. Four weeks after treatment, cardiac function by echocardiography, infarct size, capillary density in the infarct border zone, bone marrow-derived endothelial progenitor cells (EPCs), and cardiac expression of Bax were measured.
  
  
  RESULTS
  Our results demonstrated that MI animals had compromised heart parameters. DZR treatment in MI animals resulted in reduction in infarct size (P = 0.013) and improved cardiac functions in terms of fractional shortening (P = 0.004) and ejection fraction (P = 0.004). The capillary density (P = 0.008) and bone marrow-derived EPCs (P < 0.05) were higher in the MI + DZR group than those in the untreated MI group. Bax expression was down-regulated in heart tissues of MI + DZR animals (P = 0.043).
  
  
  CONCLUSIONS
  Our study demonstrated that DZR exerted a cardioprotective effect in the rat model of MI, and the mechanism might be associated with anti-apoptosis and increased neovascularization.
authors.affiliation: Department of Cardiology, Children's Hospital of Chongqing Medical University, Chongqing, PR China.
authors.forename: Ligang
authors.initials: L
authors.lastname: Zhou
authors.forename: Rita Yn Tz
authors.initials: RY
authors.lastname: Sung
authors.forename: Karen
authors.initials: K
authors.lastname: Li
authors.forename: Nga Hin
authors.initials: NH
authors.lastname: Pong
authors.forename: Ping
authors.initials: P
authors.lastname: Xiang
authors.forename: Jie
authors.initials: J
authors.lastname: Shen
authors.forename: Pak Cheung
authors.initials: PC
authors.lastname: Ng
authors.forename: Yuan
authors.initials: Y
authors.lastname: Chen
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001772:Blood Cell Count; D001854:Bone Marrow Cells / Q000166:cytology; D002196:Capillaries / Q000502:physiology; D002316:Cardiotonic Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D015536:Down-Regulation; D004452:Echocardiography; D042783:Endothelial Cells / Q000378:metabolism; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology*; D009206:Myocardium / Q000378:metabolism; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011929:Razoxane / Q000494:pharmacology*; D013234:Stem Cells / Q000378:metabolism; D013318:Stroke Volume; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: D002316:Cardiotonic Agents; D051028:bcl-2-Associated X Protein; D011929:Razoxane